Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: new frontiers in metabolic dysfunction-associated steatotic liver disease therapy

Basit Öğe Kaydı
dc.contributor.authorGüney Coşkun, Merve
dc.contributor.authorBaşaranoğlu, Metin
dc.date.accessioned2025-11-05T13:30:30Z
dc.date.available2025-11-05T13:30:30Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Beslenme ve Diyetetik Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü
dc.description.abstractThe gut-liver axis plays a crucial role in the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Key metabolites, including lipopolysaccharides, short-chain fatty acids (SCFAs), bile acids, and beneficial gut bacteria such as Bifidobacterium and Lactobacillus, are pivotal in this process. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in managing MASLD by promoting weight loss, enhancing insulin secretion, and improving liver health. They restore gut-liver axis functionality, and their effects are amplified through dietary modifications and gut microbiome-targeted therapies. Emerging research highlights the interplay between GLP-1 RAs and gut microbiota, indicating that the gut microbiome significantly influences therapeutic outcomes. Metabolites produced by gut bacteria, can stimulate glucagon-like peptide-1 (GLP-1) secretion, further improving metabolic health. Integrating dietary interventions with GLP-1 RA treatment may enhance liver health by modulating the gut microbiota-SCFAs-GLP-1 pathway. Future research is needed to understand personalized effects, with prebiotics and probiotics offering treatment avenues for MASLD.
dc.identifier.citationGüney Coşkun, M. ve Başaranoğlu, M. (2024). Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: new frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World Journal of Gastroenterology, 30(43), 4682-4688. http://dx.doi.org/10.3748/wjg.v30.i43.4682
dc.identifier.doi10.3748/wjg.v30.i43.4682
dc.identifier.endpage4688
dc.identifier.issn1007-9327
dc.identifier.issn2219-2840
dc.identifier.issue43
dc.identifier.pmid39575401
dc.identifier.scopus2-s2.0-85208226676
dc.identifier.scopusqualityQ1
dc.identifier.startpage4682
dc.identifier.urihttp://dx.doi.org/10.3748/wjg.v30.i43.4682
dc.identifier.urihttps://hdl.handle.net/20.500.12511/13163
dc.identifier.volume30
dc.identifier.wosWOS:001360211000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGüney Coşkun, Merve
dc.institutionauthorid0000-0002-5940-2413
dc.language.isoen
dc.relation.ispartofWorld Journal of Gastroenterology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectDiet Intervention
dc.subjectGlucagon-Like Peptide-1 Receptor Agonists
dc.subjectGut Microbiome
dc.subjectGut-Liver Axis
dc.subjectMetabolic Dysfunction-Associated Steatotic Liver Disease
dc.titleInterplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: new frontiers in metabolic dysfunction-associated steatotic liver disease therapy
dc.typeLetter

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Güney Coşkun-Merve-2024.pdf
Boyut:
1.19 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Sağlık Bilimleri Enstitüsü Diğer Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu